Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...

Additional signs that might be mistaken for poor circulation include pins and needles sensations, coldness at the extremities ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

We often forget to pay attention to our feet, only looking at them while in the shower, or getting a pedicure done here and ...

Behavioral economics has uncovered many ways to nudge, influence, and persuade. Now, the MINDSPACE framework has put them ...

Spreads between eurozone peripheral bond yields and Bunds were at historically tight levels and prone to widening due to tariff-related risk aversion.

Novo Nordisk announced results of the Phase IIIb STRIDE trial of semaglutide’s impact on walking capacity in people with PAD ...

Other symptoms may mimic signs of poor circulation like pins and needles, cold extremities, pale or blue skin, muscle ...

Peripheral artery disease usually occurs in the legs and can result in severe pain, gangrene or even amputation. Up to 10% of ...

Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...